Summary Next-generation anti–CTLA-4 antibodies have been designed and tested to improve the efficacy and therapeutic index by leveraging enhanced Fc-mediated effector function with conditional tumor-restricted activation. The goal is to achieve robust antitumor activity without inducing systemic immune-related toxicity. See related article by Jhatakia et al., p. 3289
Journal article
American Association for Cancer Research (AACR)
2026-08-03T00:00:00+00:00
32
3112 - 3114
2